Alton, Philip, Hughes, David M 
ORCID: 0000-0002-1287-9994 and Zhao, Sizheng Steven ORCID: 0000-0002-3558-7353
(2023)
Cardiovascular safety of genetically proxied interleukin-5 inhibition: A mendelian randomization study.
RESPIRATORY INVESTIGATION, 61 (2).
pp. 149-152.
Abstract
Interleukin-5 (IL-5) inhibitors have revolutionized the management of eosinophilic asthma. However, IL-5 is thought to play a protective role in atherosclerosis, and cardiovascular safety data for IL-5i are scarce. We used population-level data to examine the association between genetically proxied IL-5i and the risk of cardiovascular diseases. Genetic instruments for IL-5i were selected from a genome-wide association study of eosinophil count in 563,946 individuals. Genetic association data for coronary artery disease were obtained from 60,801 cases, 40,585 stroke cases, 7988 venous thromboembolism cases, and up to 406,111 controls. We used the inverse-variance weighted method and a series of sensitivity analyses. Nine genetic variants were selected to instrument IL-5i. Genetically proxied IL-5i was not associated with the risk of coronary heart disease (OR 0.82, 95%CI 0.65-1.03), stroke (OR 1.10; 0.95-1.27), or venous thromboembolism (OR 0.87; 0.64-1.17). We found no genetic evidence to suggest that IL-5i affects the risk of adverse cardiovascular and thromboembolic events.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Asthma, Cardiovascular safety, Genetic instrumental variable, IL-5, Mepolizumab |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Population Health Faculty of Health and Life Sciences > Clinical Directorate |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 24 Apr 2023 09:32 |
| Last Modified: | 24 Apr 2023 09:32 |
| DOI: | 10.1016/j.resinv.2022.12.004 |
| Open Access URL: | https://doi.org/10.1016/j.resinv.2022.12.004 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3169902 |
Dimensions
Dimensions
